PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 3, 20260 citationsOpen Access

AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation on HEV by qPCR – Virucidal compounds

View Full Paper
ABAnne Bull-Maurer

Key Result

This document provides a standard operating procedure for evaluating the antiviral efficacy of virucidal compounds against HEV in PLC3 differentiated cells using qPCR.

Key Points

  • The study aims to evaluate the antiviral activity of compounds against hepatitis E virus (HEV) while assessing cellular toxicity.
  • Evaluate cellular toxicity in PLC3 differentiated cells prior to antiviral testing.
  • Test the highest dose allowing over 90% cell viability for antiviral efficacy.
  • Quantify virus levels in the supernatants of infected cell cultures using qPCR.
  • The antiviral effect is dependent on maintaining over 90% cell viability during testing.
  • Quantitative analysis via qPCR reveals the efficacy of various antiviral compounds against HEV.

Structured PICO

P
Population
PLC3 differentiated cells for HEV infection studies
I
Intervention
virucidal compounds
O
Outcome
antiviral efficacy (quantifying viruses in the supernatants of infected cell cultures by qPCR)surrogate

This document outlines a standard operating procedure for evaluating the antiviral efficacy of virucidal compounds against HEV using qPCR in PLC3 differentiated cells.

Abstract

When evaluating the antiviral effect of a compound, assessing cellular toxicity in the target cell line is an essential prerequisite (see SOP ‘AVITHRAPID - Standard Operating Procedure - Cytotoxicity evaluation – virucidal compounds’ at https://zenodo.org/records/20486126). The highest dose allowing > 90 % cell viability is the first tested dose in antiviral assay. Quantifying viruses in the supernatants of infected cell cultures enables the evaluation of the antiviral efficacy of compounds. PLC3 differenciated cells are used for HEV infection studies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Anne Bull-Maurer (2026) studied HEV infection (in vitro). Virucidal compounds was evaluated on Antiviral efficacy (quantifying viruses in supernatants by qPCR). This document provides a standard operating procedure for evaluating the antiviral efficacy of virucidal compounds against HEV in PLC3 differentiated cells using qPCR.

synapsesocial.com/papers/6a1fc6f7dee9eb8c0dce7d50https://doi.org/10.5281/zenodo.20486323
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation by qPCR – Virucidal compounds2026
  2. 2AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation by CPE – Virucidal compounds2026
  3. 3AVITHRAPID - Standard Operating Procedure - Cytotoxicity evaluation – virucidal compounds2026
  4. 4AVITHRAPID - Standard Operating Procedure - PLC3 cells differentiation before HEV infection2026
  5. 5AVITHRAPID - Standard Operating Procedure - Antiviral Activity Assay2026